OraSure Technologies (OSUR) to Release Quarterly Earnings on Wednesday

OraSure Technologies (NASDAQ:OSUR - Get Free Report) will issue its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.04 per share for the quarter. OraSure Technologies has set its Q1 2024 guidance at EPS.Persons that are interested in participating in the company's earnings conference call can do so using this link.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) last issued its earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.09. The company had revenue of $75.88 million for the quarter, compared to analyst estimates of $74.13 million. OraSure Technologies had a net margin of 13.23% and a return on equity of 14.50%. The company's revenue for the quarter was down 38.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.21 EPS. On average, analysts expect OraSure Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OraSure Technologies Price Performance

Shares of NASDAQ OSUR traded up $0.04 during mid-day trading on Wednesday, hitting $5.33. The company's stock had a trading volume of 410,821 shares, compared to its average volume of 875,218. The stock has a market cap of $407.80 million, a price-to-earnings ratio of 7.39 and a beta of 0.15. OraSure Technologies has a one year low of $4.38 and a one year high of $8.45. The company's fifty day simple moving average is $6.27 and its 200-day simple moving average is $6.81.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on OSUR shares. Evercore ISI cut their price target on shares of OraSure Technologies from $7.00 to $6.50 and set an "in-line" rating on the stock in a research report on Thursday, April 4th. StockNews.com upgraded shares of OraSure Technologies from a "hold" rating to a "buy" rating in a research report on Wednesday. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $6.38.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.